Safety considerations of fluoroquinolones in the elderly: An update

Drugs and Aging

Volumn 27, Issue 3, 2010, Pages 193-209

  Stahlmann, Ralf ^a   Lode, Hartmut ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CAFFEINE; CIPROFLOXACIN; CLINAFLOXACIN; CLOZAPINE; COTRIMOXAZOLE; DIZOCILPINE; ERYTHROMYCIN; FLEROXACIN; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PARACETAMOL; PEFLOXACIN; PENICILLIN G; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SULFONAMIDE; THEOPHYLLINE; TOSUFLOXACIN; TROVAFLOXACIN; UNINDEXED DRUG;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGING; AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ANOREXIA; ANTIBACTERIAL ACTIVITY; ANXIETY; AREA UNDER THE CURVE; ARTHROPATHY; BRAIN TOXICITY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONFUSION; CONSTIPATION; CREATININE CLEARANCE; CRYSTALLURIA; DEPRESSION; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EOSINOPHILIA; ERYTHEMA MULTIFORME; EUPHORIA; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART ARRHYTHMIA; HEPATITIS; HUMAN; HYPERGLYCEMIA; INSOMNIA; INTERSTITIAL NEPHRITIS; KIDNEY FUNCTION; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEPHROTOXICITY; NERVOUSNESS; NIGHTMARE; NONHUMAN; OBSTRUCTIVE JAUNDICE; PERIPHERAL EDEMA; PHOTOTOXICITY; PRIORITY JOURNAL; PSYCHOSIS; PURPURA; QT PROLONGATION; RESTLESSNESS; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN MANIFESTATION; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; TENDINITIS; TENDON RUPTURE; THRUSH; TORSADE DES POINTES; TOXIC EPIDERMAL NECROLYSIS; TREMOR; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION; URINARY TRACT INFECTION; URINARY TRACT OBSTRUCTION; UROLITHIASIS; WEAKNESS;

AGED; AGED, 80 AND OVER; AGING; AREA UNDER CURVE; ELECTROCARDIOGRAPHY; FLUOROQUINOLONES; HUMANS; KIDNEY FAILURE; MIDDLE AGED;

EID: 77949366024     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11531490-000000000-00000     Document Type: Review

References (91)

1. Naber KG, Adam D. Classification of fluoroquinolones. Int J Antimicrob Agents 1998; 10: 255-257
2. Stahlmann R, Lode H. Fluoroquinolones in the elderly: safety considerations. Drugs Aging 2003; 20 (4): 289-302.
3. Carbonin P, Pahor M, Bernabei R, et al. Is age an in-dependent risk factor of adverse drug reactions in hospitalized medical patients? J Am Geriatr Soc 1991; 39: 1093-1099
4. Mamdani M, McNeely D, Evans G, et al. Impact of a fluoroquinolone restriction policy in an elderly population. Am J Med 2007; 120: 893-900.
5. Iannini PB. The safety profile of moxifloxacin and other fluoroquinolones in special patient populations [published erratum appears in Curr Med Res Opin 2007; 23 (9): 2303]. Curr Med Res Opin 2007; 23 (6): 1403-1413
6. Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections [corrected and repub-lished in J Antimicrob Chemother 2002; 50 (1): 151-4]. J Antimicrob Chemother 2002; 49 (5): 709-712
7. Gomolin IH, Siami PF, Reuning-Scherer J, et al., and Oral Suspension Study Group. Efficacy and safety of ciproflox-acin oral suspension versus trimethoprim/sulfamethoxa-zole oral suspension for treatment of older women with acute urinary tract infection. J Am Geriatr Soc 2001; 49: 1606-1613
8. Noreddin AM, Hoban DJ, Zhanel GG. Comparison of ga-tifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int J Antimicrob Agents 2005; 26 (2): 120-125
9. Andriole VT, Haverstock DC, Choudhri SH. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials. Drug Saf 2005; 28 (5): 443-452
10. Ball P, File TM, Twynholm M, et al. Efficacy and safety of gemifloxacin 320mg once-daily for 7 days in the treatment of adult lower respiratory tract infections. Int J Antimicrob Agents 2001; 18 (1): 19-27.
11. Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42: 73-81.
12. Shorr AF, Zadeikis N, Xiang JX, et al. A multicenter, ran-domized, double-blind, retrospective comparison of 5-and 10-day regimens of levofloxacin in a subgroup of patients aged or =65 years with community-acquired pneumonia. Clin Ther 2005; 27 (8): 1251-1259
13. Nicholson SC, High KP, Gothelf S, et al. Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly. Diagn Microbiol Infect Dis 2002; 44 (1): 109-116
14. Keam SJ, Croom KF, Keating GM. Gatifloxacin: a review of its use in the treatment of bacterial infections in the US. Drugs 2005; 65 (5): 695-724.
15. Graber H, Ludwig E, Arr M, et al. Difference in multiple-dose pharmacokinetics of ofloxacin in young and aged patients [abstract no. 94]. International Symposium on New Quinolones; 1986 Jul 17-19; Geneva.
16. Chien SC, Chow AT, Natarajan J, et al. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997; 41: 1562-1565
17. Perry CM, Ormrod D, Hurst M, et al. Gatifloxacin: a review of its use in the management of bacterial infections. Drugs 2002; 62 (1): 169-207.
18. Tequin™ (gatifloxacin) [US package insert]. Princeton (NJ): Bristol-Myers Squibb Company 2001.
19. Balfour JA, Lamb HM. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000; 59 (1): 115-139
20. Wiseman LR, Balfour JA. Ciprofloxacin: a review of its pharmacological profile and therapeutic use in the elderly. Drugs Aging 1994; 4 (2): 145-173
21. van Zanten AR, Polderman KH, van Geijlswijk IM, et al. Ciprofloxacin pharmacokinetics in critically ill patients: a prospective cohort study. J Crit Care 2008; 23 (3): 422-430
22. Bhavnani SM, Andes DR. Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 2005; 25 (5): 717-740
23. Lode HM, Schmidt-Ionas M, Stahlmann R. Gemifloxacin for community-acquired pneumonia. Expert Opin Investig Drugs 2008; 17 (5): 779-786
24. Nicolle LE. Quinolones in the aged. Drugs 1999; 58 Suppl. 2: 49-51.
25. Breen J, Skuba K, Grasela D. Safety and tolerability of gatifloxacin, an advanced-generation, 8-methoxy fluoroquinolone. J Resp Dis 1999; 20 Suppl.: S70-6.
26. Springsklee M, Reiter C, Meyer JM. Safety and tolerability of moxifloxacin (MXF) [abstract no. 260]. Antiinfect Drugs Chemother 2000; 17 (1): 90.
27. Ball P, Stahlmann R, Kubin R, et al. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004; 26 (7): 940-950
28. Levaquin®: prescribing information. Raritan (NJ): Ortho-McNeil 1999.
29. Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs 1999; 58 Suppl. 2: 65-70.
30. Edlund C, Beyer G, Hiemer-Bau M, et al. Comparative ef-fects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis 2000; 32: 81-85
31. Ljungberg B, Nilsson-Ehle I, Edlund C, et al. Influence of ciprofloxacin on the colonic microflora in young and elderly volunteers: no impact of the altered drug absorption. Scand J Infect Dis 1990; 22: 205-208
32. Bartlett JG. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 2002; 346 (5): 334-339
33. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Inf Dis 2005; 41 (9): 1254-1260
34. Rao GG, Rao CSM, Starke I. Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with P-lactam-based therapy. J Antimicrob Chemother 2003; 51: 697-701.
35. Mendez MN, Gibbs L, Jacobs RA, et al. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections. Pharmacother 2006; 26 (1): 61-67
36. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003; 51 (6): 1339-1350
37. Blondeau JM. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J Antimicrob Chemother 2009; 63 (2): 238-242
38. Mehlhorn AJ, Brown DA. Safety concerns with fluoro-quinolones. Ann Pharmacother 2007; 41 (11): 1859-1866
39. Stahlmann R. Clinical toxicological aspects of fluoro-quinolones. Toxicol Lett 2002; 127: 269-277
40. Kawahara K, Kawahara M, Goto T, et al. Penetration of sparfloxacin into the human spinal fluid: a comparative study with 5 other fluoroquinolones. Chemotherapy 1991; 39: 149-157
41. Davey PG, Charter M, Kelly S, et al. Ciprofloxacin and sparfloxacin penetration into human brain tissue and their activity as antagonists of GABAA receptor of rat vagus nerve. Antimicrob Agents Chemother 1994; 38: 1356-1362
42. Leone M, Sampol-Manos E, Santelli D, et al. Brain tissue penetration of ciprofloxacin following a single intravenous dose. J Antimicrob Chemother 2002; 50 (4): 607-609
43. Kushner JM, Peckman HJ, Snyder CR. Seizures associated with fluoroquinolones. Ann Pharmacother 2001; 35: 1194-1198
44. Takayama S, Hirohashi M, Kato M, et al. Toxicity of quinolone antimicrobial agents. J Toxicol Environment Health 1995; 45: 1-45.
45. Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 2005; 41: S144-57.
46. Schmuck G, Schurmann A, Schluter G. Determination of the excitatory potencies of fluoroquinolones in the central nervous system by an in vitro model. Antimicrob Agents Chemother 1998; 42: 1831-1836
47. Shakeri-Nejad K, Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 2006; 7 (6): 639-651
48. Brouwers EE, Sohne M, Kuipers S, et al. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clin Drug Investig 2009; 29: 59-63.
49. Lipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28: 352-364
50. Van Bambeke F, Tulkens PM. Safety profile of the re-spiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes. Drug Saf 2009; 32 (5): 359-378
51. Ball P, Mandell L, Patou G, et al. A new respiratory fluor-oquinolone, oral gemifloxacin: a safety profile in context. Int J Antimicrob Agents 2004; 23: 421-429
52. Rubinstein E, Camm J. Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 2002; 49: 593-596
53. Anderson ME, Mazur A, Yang T, et al. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. J Pharmacol Exp Ther 2001; 296 (3): 806-810
54. + channel HERG. Mol Pharmacol 2001; 59: 122-126
55. Church D, Haverstock D, Andriole VT. Moxifloxacin: a review of its safety profile based on worldwide clinical trials. Todays Therapeutic Trends 2000; 18: 205-223
56. Bertino JS, Owens RC, Carnes TD, et al. Gatifloxacin-associated corrected QT-interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors. Clin Infect Dis 2002; 34: 861-863
57. Owens RC, Ambrose PG. Torsades de pointes associated with fluoroquinolones. Pharmacotherapy 2002; 22: 663-668
58. Amankwa K, Krishnan SC, Tisdale JE. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Clin Pharmacol Ther 2004; 75 (3): 242-247
59. Morganroth J, DiMarco JP, Anzueto A, et al. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs levofloxacin in elderly patients hospitalized with community-acquired pneumonia. Chest 2005; 128: 3398-3406
60. Avelox™ (moxifloxacin hydrochloride) tablets [US package insert]. Wayne (NJ): Bayer HealthCare Pharmaceuticals Inc. 1999.
61. Sherman O, Beizer JL. Possible ciprofloxacin-induced acute cholestatic jaundice. Ann Pharmacother 1994; 28 (10): 1162-1164
62. Ho CC, Chen YC, Hu FC, et al. Safety of fluoroquinolone use in patients with hepatotoxicity induced by antituberculosis regimens. Clin Infect Dis 2009; 48 (11): 1526-1533
63. Lode HM, Schmidt-Ionas M. Moxifloxacin: update and perspectives after 8 years of usage. Exp Rev Resp Med 2008; 2: 443-453
64. Shlaes DM, Moellering RC. Telithromycin and the FDA: implications for the future. Lancet Infect Dis 2008; 8 (2): 83-85
65. Grayson ML. Synthetic antibacterial and antiparasitic drugs. In: Kucers A, Crowe SM, Grayson ML, et al., editors. The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs. 5th ed. Oxford: Butterworth, Heinemann, 1997: 981-1060.
66. Lomaestro BM. Fluoroquinolone-induced renal failure. Drug Saf 2000; 22: 479-485
67. Famularo G, De Simone C. Nephrotoxicity and purpura associated with levofloxacin. Ann Pharmacother 2002; 36 (9): 1380-1382
68. Ramalakshmi S, Bastacky S, Johnson JP. Levofloxacin-induced granulomatous interstitial nephritis [abstract]. Am J Kidney Dis 2003; 41 (2): E7.
69. Stratta P, Lazzarich E, Canavese C, et al. Ciprofloxacin crystal nephropathy. Am J Kidney Dis 2007; 50 (2): 330-335
70. Chopra N, Fine PL, Price B, et al. Bilateral hydronephrosis from ciprofloxacin induced crystalluria and stone formation. J Urology 2000; 164:438.
71. Sendzik J, Lode H, Stahlmann R. Quinolone-induced ar-thropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents 2009; 33 (3): 194-200.
72. Forster C, Kociok K, Shakibaei M, et al. Quinolone-induced cartilage lesions are not reversible in rats. Arch Toxicol 1996; 70: 474-481
73. Forster C, Schwabe R, Lozo E, et al. Quinolone-induced arthropathy: exposure of magnesium-deficient aged rats or immature rats, mineral concentrations in target tissues and pharmacokinetics. Arch Toxicol 1997; 72: 26-32.
74. Stahlmann R, Forster C, Shakibaei M, et al. Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical with quinolone-induced arthropathy. Antimicrob Agents Chemother 1995; 39: 2013-2018
75. Lozo E, Riecke K, Schwabe R, et al. Synergistic effect of ofloxacin and magnesium deficiency on joint cartilage in immature rats. Antimicrob Agents Chemother 2002; 46: 1755-1759
76. Pfister K, Mazur D, Vormann J, et al. Diminished cipro-floxacin-induced chondrotoxicity by supplementation with magnesium and vitamin E in immature rats. Antimicrob Agents Chemother 2007; 51 (3): 1022-1027
77. Van der Linden PD, van Puijenbroek EP, Feenstra J, et al. Tendon disorders attributed to fluoroquinolones: a study on 42 spontaneous reports in the period 1988 to 1998. Arthritis Rheum 2001; 45: 235-239
78. Damuth E, Heidelbaugh J, Malani PN, et al. An elderly patient with fluoroquinolone-associated Achilles tendinitis. Am J Geriatr Pharmacother 2008; 6 (5): 264-268
79. Parmar C, Meda KP. Achilles tendon rupture associated with combination therapy of levofloxacin and steroid in four patients and a review of the literature. Foot Ankle Int 2007; 28: 1287-1289
80. Vyas H, Krishnaswamy G. Images in clinical medicine. Quinolone-associated rupture of the Achilles' tendon [letter]. N Engl J Med 2007; 357 (20): 2067.
81. Kahn MF, Hayem G. Tendons and fluoroquinolones: un-resolved issues. Rev Rhum Engl Ed 1997; 64: 437-439
82. Pierfitte C, Royer RJ. Tendon disorders with fluoro-quinolones. Therapie 1996; 51: 419-420
83. Van der Linden PD, van de Lei J, Nab HW, et al. Achilles tendinitis associated with fluoroquinolones. Br J Clin Pharmacol 1999; 48: 433-437
84. Simonin M-A, Gegout-Pottie P, Minn A, et al. Pefloxacin-induced Achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen. Antimicrob Agents Chemother 2000; 44: 867-872
85. Shakibaei M, Pfister K, Schwabe R, et al. Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet. Antimicrob Agents Chemother 2000; 44: 261-266
86. Shakibaei M, Stahlmann R. Ultrastructure of Achilles ten-don from rats after treatment with fleroxacin. Arch Toxicol 2001; 75: 97-102.
87. Shakibaei M, Baumann-Wilschke I, Stahlmann R. Quinolone-induced changes in Achilles tendons from rats persist for several months [poster no. P130]. J Antimicrob Chemother 2001; 47 Suppl. S1: 49.
88. Saraya A, Yokokura M, Gonoi T, et al. Effects of fluoro-quinolones on insulin secretion and beta-cell ATP-sensitive K+ channels. Eur J Pharmacol 2004; 497 (1): 111-117
89. Ambrose PG, Bhavnani SM, Owens Jr RC. Clinical phar-macodynamics of quinolones. Infect Dis Clin North Am 2003; 17 (3): 529-543
90. Ambrose PG, Bhavnani SM, Cirincione BB, et al. Gati-floxacin and the elderly: pharmacokinetic-pharmacody-namic rationale for a potential age-related dose reduction. J Antimicrob Chemother 2003; 52 (3): 435-440
91. Park-Wyllie LY, Juurlink DN, Kopp A, et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354 (13): 1352-1361